TO THE EDITOR-We have read with great interest the recent articles by Tenorio et al and Hunt et al that investigated inflammation, coagulation, and T-cell activation as predictors of clinical outcome in human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy (cART) [1, 2] . Interestingly, while inflammation/coagulation and gut damage were independently associated with mortality and non-AIDS morbidity, T-cell activation was not significantly related to these outcomes.
CD38 is commonly regarded as a Tcell activation marker, and circulating CD38 + CD8 + T cells have been strongly correlated with disease progression in untreated HIV infection [3, 4] . Upon suppressive cART, levels of CD38 + CD8 + T cells remain abnormally elevated [5] , and yet their prognostic significance is less clear [6, 7] . ; HIV RNA load, <40 copies/mL; median time to first suppression, 4 years), and 10 were HIV-negative healthy donors (controls).
As expected, untreated HIV-positive patients displayed a higher proportion of CD8 + CD38 + cells than HIV-negative subjects (28% vs 8%; P = .0001). HIVpositive cART recipients showed decreased CD8 + CD38 + levels, which, however, remained higher than those measured in controls (17% vs 8%; P = .004).
As shown in Figure 1A , + CD8 + T cells were either left unstimulated or stimulated with anti-CD3/CD28 (3/28) antibodies alone, or together with 100 U recombinant interleukin 2 (rIL-2) or 1000 pg/mL recombinant interleukin 7 (rIL-7), and levels of pSTAT and Bcl-2 expression were determined using intracellular flow cytometry (after 5 hours for pSTAT and after 24 hours for Bcl-2). C, Analysis of total HIV DNA (integrated and unintegrated HIV DNA forms), unintegrated HIV DNA (extrachromosomal HIV DNA species), integrated HIV DNA, and 2 long-terminal repeat (2-LTR) circle content. were observed in HIV-positive cART recipients, compared with untreated subjects ( pSTAT-5, P = .036; Bcl-2, P = .032; Figure 1B ), and these levels were significantly lower than those for HIV-negative subjects ( pSTAT-5, P = .046; Bcl-2, P = .036). In 10 HIV-positive cART recipients, no significant differences in total, unintegrated, and integrated HIV DNA [10] were noted in purified CD4 + CD38 + and CD4 + CD38 − T cells ( Figure 1C ). 
